AstraZeneca’s (AZN) Imfinzi has been approved in the U.S. for the treatment of adult patients with limited-stage small cell lung cancer, or LS-SCLC, whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Imfinzi approved in U.S. as immunotherapy regimen for LS-SCLC
- AstraZeneca appoints Iskra Reic as Executive Vice President, International
- AstraZeneca (AZN) Sees Its Cancer Drug Added to China’s Reimbursement List
- AstraZeneca announces results from CAPItello-281 trial
- AstraZeneca’s Truqap combo demonstrated statistically significant improvement